Adient (ADNT) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Annual General Meeting scheduled for March 11, 2025, at the Radisson Blu Hotel Dublin Airport, Dublin, Ireland.
Shareholders can vote online, by mail, or in person, with voting deadlines set for March 6 and March 9, 2025, depending on shareholding method.
Voting matters and shareholder proposals
Election of eight directors is on the agenda, with individual nominees listed.
Advisory vote to ratify PricewaterhouseCoopers LLP as independent auditor for fiscal year 2025 and authorize the Board to set auditor remuneration.
Advisory vote on named executive officer compensation (say-on-pay).
Proposal to renew Board authority to issue shares under Irish law.
Proposal to approve the amended and restated 2021 Omnibus Incentive Plan.
Proposal to renew Board authority to opt out of statutory preemption rights under Irish law.
Board of directors and corporate governance
Eight director nominees are presented for election at the meeting.
Board recommends voting in favor of all director nominees and proposals.
Latest events from Adient
- Q1 FY26 saw 4% revenue growth and raised guidance, driven by China, innovation, and new wins.ADNT
Q1 20264 Feb 2026 - Disciplined capital allocation, innovation, and regional growth drive margin expansion and value.ADNT
Deutsche Bank Global Auto Industry Conference 20253 Feb 2026 - Margin expansion and innovation drive growth, with China focus and restructuring prioritized.ADNT
J.P. Morgan Auto Conference 20242 Feb 2026 - Q3 sales dropped 8% and net loss hit $11M, but cash flow and buybacks stayed strong.ADNT
Q3 20242 Feb 2026 - Proxy covers director elections, auditor ratification, compensation, and share issuance authority.ADNT
Proxy Filing21 Jan 2026 - Director elections, auditor ratification, and Board authority renewals up for shareholder vote.ADNT
Proxy Filing21 Jan 2026 - Margin expansion and strong cash flow in FY24, with China and EMEA as key focus areas.ADNT
Q4 202415 Jan 2026 - Q1 FY2025: $196M EBITDA, $45M cash flow, EMEA weak, guidance trimmed, liquidity strong.ADNT
Q1 20259 Jan 2026 - Director elections, auditor ratification, and executive pay alignment headline the 2025 agenda.ADNT
Proxy Filing1 Dec 2025